Browse > Article

Analysis on Statins for The Treatment of Bone Fracture  

Choi, Byung-Chul (College of Pharmacy, Chung-Ang University)
Publication Information
YAKHAK HOEJI / v.53, no.4, 2009 , pp. 206-216 More about this Journal
Abstract
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (Statins) are potent inhibitors of cholesterol biosynthesis. Cholesterol-lowering therapy using statins significantly reduces the risk of coronary heart disease. Various discovery of statins as bone anabolic agents has spurred a great deal of interest among both basic and clinical bone researchers. In-vitro and some animal studies suggest that statins increase the bone mass by enhancing bone morphogenetic protein-2 (BMP-2)-mediated osteoblast expression. Clinical and animal test results of statins focusing on the prevention and treatment of bone fractures was collected. Three independent literature searches were performed by using from January 1, 2002 to September 2008 for clinical and animal test results. Search term included statins, HMG-CoA reductase inhibitors, pleiotropic effects, fracture, osteoporosis and clinical and animal test. No consensus has been reached whether clinical use of statins has beneficial effects on bone health, partly due to lower statin concentrations because of first-pass metabolism by the liver. Experimental use of statins as stimulators of bone formation suggests that they may have widespread applicability in the field of orthopaedics. With their combined effects on osteoblasts and osteoclasts, statins have the potential to enhance resorption of synthetic materials and improve bone ingrowth. In conclusion, The use of statins in the prevention and treatment of bone fractures requires further study. But observational studies suggest that statins for decreasing bone fractures including osteoporosis have to be considered local direct administration like transdermal or subcutaneous type over oral adminstration.
Keywords
statins; HMG-CoA reductase inhibitors; pleiotropic effects; osteoporosis; bone fracture; local application;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Endo, A. : The discovery and development of HMG-CoA reductase inhibitors. J. Lipid Res. 33, 1569 (1992)   PUBMED
2 Wolozin, B., Wang, S. W., Li, N. C., Lee, A., Lee, T. A. and Kazis, L. E. : Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med. 5, 20 (2007)
3 Ohnaka, K. and Takayanagi, R. : Statin and BMP. Clin. Calcium. 14, 286 (2004)   PUBMED
4 Ruiz-Gaspa, S., Nogues, X., Enjuanes, A., Monllau, J. C., Blanch, J., Carreras, R., Mellibovsky, L., Grinberg, D., Balcells, S., Dez-Perez, A. and Pedro-Botet, J. : Simvastatin and atorvastatin enhance gene expression of collagen type 1 and osteocalcin in primary human osteoblasts and MG-63 cultures. J. Cell. Biochem. 101, 1430 (2007)   DOI   ScienceOn
5 Song, C., Wang, J., Song, Q., Li, X., Chen, Z., Ma, Q., Liu, Z., Jia, H. and Dang, G. : Simvastatin induces estrogen receptoralpha (ER-alpha) in murine bone marrow stromal cells. J. Bone Miner. Metab. 26, 213 (2008)   DOI   PUBMED
6 Majima, T., Shimatsu, A., Komatsu, Y., Satoh, N., Fukao, A., Ninomiya, K., Matsumura, T. and Nakao, K. : Short-term effects of pitavastatin on biochemical markers of bone turnover in patients with hypercholesterolemia. Intern. Med. 46, 1967 (2007)   DOI   ScienceOn
7 Cushenberry, L. M. and de Bittner, M. R. : Potential use of HMG-CoA reductase inhibitors for osteoporosis. Ann. Pharmacother. 36, 671 (2002)   DOI   ScienceOn
8 Gonyeau, M. J. : Statins and osteoporosis: a clinical review. Pharmacotherapy 25, 228 (2005)   DOI   PUBMED   ScienceOn
9 Schlienger, R. G. and Meier, C. R. : HMG-CoA reductase inhibitors in osteoporosis: do they reduce the risk of fracture? Drugs Aging 20, 321 (2003)   DOI   ScienceOn
10 Mundy, G., Garrett, R., Harris, S., Chan, J., Chen, D., Rossini, G., Boyce, B., Zhao, M. and Gutierrez, G. : Stimulation of bone formation in vitro and in rodents by statins. Science 286, 1946 (1999)   DOI   PUBMED   ScienceOn
11 Nichols, R., Hopman, W. M., Morton, A. R., Harman, G. J. and Holden, R. M. : Statins are associated with a reduced risk of bone fracture in hemodialysis (HD) patients. Hemodial. Int. 12, 175 (2008)
12 Richard, E., Scranton, M. D., Melissa, Y., Elizabeth, L., Daniel, S., David, G. and Michael, G. : Statin Use and Fracture Risk. Arch. Intern. Med. 165, 2007 (2005)   DOI   ScienceOn
13 Schoofs, M. W., Sturkenboom, M. C., van der Klift, M., Hofman, A., Pols, H. A. and Stricker, B. H. : HMG-CoA reductase inhibitors and the risk of vertebral fracture. J. Bone Miner. Res. 19, 152 (2004)
14 Moriyama, Y., Ayukawa, Y., Ogino, Y., Atsuta, I. and Koyano, K. : Topical application of statin affects bone healing around implants. Clin. Oral Implants Res. 19, 600 (2008)   DOI   ScienceOn
15 LaCroix, A. Z., Cauley, J. A., Pettinger, M., Hsia, J., Bauer D. C., McGowan, J., Chen, Z., Lewis, C. E., McNeeley, S. G., Passaro, M. D. and Jackson, R. D. : Statin use, clinical fracture, and bone density in postmenopausal women: results from the women's health initiative observational study. Ann. Intern. Med. 139, 97 (2003)   DOI   PUBMED   ScienceOn
16 Mauro, V. F. and MacDonald, J. L. : Simvastatin: a review of its pharmacology and clinical use. Dalian Inst. Chem. Phys. 25, 257 (1991)
17 Gaw, A., Packard, C. J. and Shepherd, J. : Statins; The HMGCoA Reductase Inhibitors in Perspective. 2nd edition. London, Martin Dunitz, p340 (2004)
18 Bielinska, A. and Gluszko, P. : Statins - are they potentially useful in rheumatology? Pol. Arch. Med. Wewn. 117, 420 (2007)
19 Shaw, S. M., Fildes, J. E., Yonan, N. and Williams, S. G. : Pleiotropic effects and cholesterol-lowering therapy. Cardiology 112, 4 (2008)   DOI   ScienceOn
20 Fried, L. F. : Effects of HMG-CoA reductase inhibitors(statins) on progression of kidney disease. Kidney Int. 74, 571 (2008)   DOI   PUBMED   ScienceOn
21 Rejnmark, L., Buus, N. H., Vestergaard, P., Andreasen, F., Larsen, M. L. and Mosekilde, L. : Statins decrease bone turnover in postmenopausal women: a cross-sectional study. Eur. J Clin. Invest. 32, 581 (2002)   DOI   ScienceOn
22 De Leo, V., Morgante, G., la Marca, A., Lanzetta, D., Cobellis, L. and Petraglia, F. : Combination of statins and hormone replacement therapy in postmenopausal women is associated with increased bone mineral density. Gynecol. Endocrinol. 17, 329 (2003)
23 Wang, P. S., Solomon, D. H., Mogun, H. and Avorn, J. : HMGCoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 283, 3211 (2000)   DOI   ScienceOn
24 Svejda, P., Soska, V. and Soucek, M. : The impact of statin therapy on bone density changes in postmenopausal women. Vnitr. Lek. 53, 1064 (2007)
25 Coons, J. C. : Hydroxymethylglutaryl-coenzyme A reductase inhibitors in osteoporosis management. Ann. Pharmacother. 36, 3260 (2002)
26 Gutierrez, G. E., Edwards, J. R., Garrett, I. R., Nyman, J. S., McCluskey, B., Rossini, G., Flores, A., Neidre, D. B. and Mundy, G. R. : Transdermal lovastatin enhances fracture repair in rats. J. Bone Miner. Res. 23, 1722 (2008)   DOI   ScienceOn
27 Skoglund, B. and Aspenberg, P. : Locally applied Simvastatin improves fracture healing in mice. BMC Musculoskelet. Disord. 8, 98 (2007)   DOI   PUBMED   ScienceOn
28 Yazawa, H., Zimmermann, B., Asami, Y. and Bernimoulin, J. P. : Simvastatin promotes cell metabolism, proliferation, and osteoblastic differentiation in human periodontal ligament cells. J. Periodontol. 76, 295 (2005)   DOI   ScienceOn
29 Jones, P. H., Davidson, M. H., Stein, E. A., Bays, H. E., McKenney, J. M., Miller, E., Cain, V. A. and Blasetto, J. W. : Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am. J. Cardiol. 92, 152 (2003)
30 Benoit, D. S., Nuttelman, C. R., Collins, S. D. and Anseth, K. S. : Synthesis and characterization of a fluvastatin-releasing hydrogel delivery system to modulate hMSC differentiation and function for bone regeneration. Biomaterials 27, 6102 (2006)   DOI   ScienceOn
31 Ray, W. A., Daugherty, J. R. and Griffin, M. R. : Lipid-lowering agents and the risk of hip fracture in a Medicaid population. Inj. Prev. 8, 276 (2002)   DOI   ScienceOn
32 OzeI., KiliE., GmC. and Gze, F. : Effect of local simvastatin application on mandibular defects. J. Craniofac. Surg. 18, 546 (2007)   DOI   ScienceOn
33 Bocan, T. M. : Pleiotropic effects of HMG-CoA reductase inhibitors. Curr. Opin. Investig. Drugs 3, 1312 (2002)
34 Lee, O. K., Ko, Y. C., Kuo, T. K., Chou, S. H., Li, H. J., Chen, W. M., Chen, T. H. and Su, Y. : Fluvastatin and lovastatin but not pravastatin induce neuroglial differentiation in human mesenchymal stem cells. Cell Biochem. 93, 917 (2004)   DOI   ScienceOn
35 Ahn, K. S., Sethi, G., Chaturvedi, M. M. and Aggarwal, B. B. : Simvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, suppresses osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand through modulation of NF-kappaB pathway. Int. J. Cancer 123, 1733 (2008)   DOI   ScienceOn
36 Kolanczyk, M., Khnisch, J., Kossler, N., Osswald, M., Stumpp, S., Thurisch, B., Kornak, U. and Mundlos, S. : Modelling neurofibromatosis type 1 tibial dysplasia and its treatment with lovastatin. BMC Medicine 6, 21 (2008)
37 Rejnmark, L., Vestergaard, P. and Mosekilde, L. : Statin but not non-statin lipid-lowering drugs decrease fracture risk: a nation-wide case-control study. Calcif, Tissue Int. 79, 27 (2006)   DOI   ScienceOn
38 Robert, H. and Knopp. : Drug Treatment of Lipid Disorders. N. Engl. J. Med. 341, 2020 (1999)   DOI   PUBMED
39 Viccica, G., Vignali, E. and Marcocci, C. : Role of the cholesterol biosynthetic pathway in osteoblastic differentiation. J. Endocrinol. Invest. 30, 8 (2007)   PUBMED
40 Tanriverdi, H. A., Barut, A. and Sarikaya, S. : Statins have additive effects to vertebral bone mineral density in combination with risedronate in hypercholesterolemic postmenopausal women. Eur. J. Obstet. Gynecol. Reprod. Biol. 120, 63 (2005)   DOI   ScienceOn
41 Adah, F., Benghuzzi, H., Tucci, M., Russell, G. and England, B. : Cholesterol production inhibitor (statin) increased bone healing in surgically created femoral defect in an animal model. Biomed. Sci. Instrum. 43, 95 (2007)   PUBMED
42 Mauro, V. F. : Clinical pharmacokinetics and practical applications of simvastatin. Clin. Pharmacokinet. 24, 195 (1993)   DOI   PUBMED   ScienceOn
43 Nyan, M., Sato, D., Oda, M., Machida, T., Kobayashi, H., Nakamura, T. and Kasugai, S. : Bone formation with the combination of simvastatin and calcium sulfate in critical-sized rat calvarial defect. J. Pharmacol. Sci. 104, 384 (2007)   DOI   ScienceOn
44 Vickers, S., Duncan, C. A., Chen, I. W., Rosegay, A. and Duggan, D. E. : Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug. Drug Metab. Dispos. 18, 138 (1990)
45 Funkhouser, H. L., Adera, T. and Adler, R. A. : Effect of HMGCoA reductase inhibitors (statins) on bone mineral density. J. Clin. Densitom. 5, 151 (2002)   DOI   ScienceOn
46 Jones, P. H., Hunninghake, D. B., Ferdinand, K. C., Stein, E. A., Gold, A., Caplan, R. J. and Blasetto, J. W. : : Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin. Ther. 26, 1388 (2004)   DOI   PUBMED   ScienceOn
47 Julie, A. P., Mark, A. K., Margaret, J. H., Kerrie, M. S. and Geoffrey, C. N. : Statin use, bone mineral density, and fracture risk: Geelong osteoporosis study. Arch. Intern. Med. 162, 537 (2002)   DOI   ScienceOn
48 Ma, B., Clarke, S. A., Brooks, R. A. and Rushton, N. : The effect of simvastatin on bone formation and ceramic resorption in a peri-implant defect model. Acta. Biomater. 4, 149 (2008)   DOI   ScienceOn
49 Wong, R. W. and Rabie, A. B. : Statin-induced osteogenesis uses in orthodontics: a scientific review. World J. Orthod. 7, 35 (2006)   PUBMED
50 Staal, A., Frith, J. C., French, M. H., Swartz, J., Gngr, T., Harrity, T. W., Tamasi, J., Rogers, M. J. and Feyen, J. H. : The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity. J. Bone Miner. Res. 18, 88 (2003)   DOI   ScienceOn
51 Jadhav, S. B., Narayana Murthy, P. S., Singh, M. M. and Jain, G. K. : Distribution of lovastatin to bone and its effect on bone turnover in rats. J. Pharm. Pharmacol. 58, 1415 (2006)   DOI   ScienceOn
52 Richard, N. M., Glen, B., Jean, K. C., Alan, M. H., Thomas, T. N. and John, C. V. : Biosynthesis of the hypocholesterolemic agent mevinolin by Aspergillus terreus. Determination of the origin of carbon, hydrogen and oxygen by 13C NMR and mass spectrometry. J. Am. Chem. Soc. 107, 3694 (1985)   DOI
53 Baldini, V., Mastropasqua, M., Francucci, C. M. and D'Erasmo, E. : Cardiovascular disease and osteoporosis. J. Endocrinol. Invest. 28, 69 (2005)   PUBMED
54 Horiuchi, N. and Maeda, T. : Statins and bone metabolism. Oral Dis. 12, 85 (2006)   DOI   ScienceOn
55 Bharti, A. C., Takada, Y. and Aggarwal, B. B. : Curcumin (diferuloylmethane) inhibits receptor activator of NF-kappa B ligand-induced NF-kappa B activation in osteoclast precursors and suppresses osteoclastogenesis. J. Immunol. 172, 5940 (2004)   DOI
56 Cruz, A. C. and Gruber, B. L. : Statins and osteoporosis: can these lipid-lowering drugs also bolster bones? Cleve. Clin. J. Med. 69, 277 (2002)   DOI   ScienceOn
57 Yaturu, S. : Skeletal effects of statins. Endocr. Pract. 9, 315 (2003)   DOI   ScienceOn
58 Lennernas, H. and Fager, G. : Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin. Pharmacokinet. 32, 403 (1997)   DOI   ScienceOn
59 Meier, C. R., Schlienger, R. G., Kraenzlin, M. E., Schlegel, B. and Jick, H. : HMG-CoA reductase inhibitors and the risk of fractures. JAMA 283, 3205 (2000)
60 Gutierrez, G. E., Lalka, D., Garrett, I. R., Rossini, G. and Mundy, G. R. : Transdermal application of lovastatin to rats causes profound increases in bone formation and plasma concentrations. Osteoporos. Int. 17, 1033 (2006)   DOI   ScienceOn
61 Skoglund, B., Forslund, C. and Aspenberg, P. : Simvastatin improves fracture healing in mice. J. Bone Miner. Res. 17, 2004 (2002)   DOI   ScienceOn
62 von Knoch, F., Wedemeyer, C., Heckelei, A., Saxler, G., Hilken, G., Brankamp, J., Sterner, T., Landgraeber, S., Henschke, F., Ler, F. and von Knoch, M. : Promotion of bone formation by simvastatin in polyethylene particle-induced osteolysis. Biomaterials 26, 5783 (2005)   DOI   ScienceOn
63 Garrett, I. R., Gutierrez, G. E., Rossini, G., Nyman, J., McCluskey, B., Flores, A. and Mundy, G. R. : Locally delivered lovastatin nanoparticles enhance fracture healing in rats. J. Orthop. Res. 25, 1351 (2007)   DOI   ScienceOn
64 Yao, W., Farmer, R., Cooper, R., Chmielewski, P. A., Tian, X. Y., Setterberg, R. B., Jee, W. S. and Lundy, M. W. : Simvastatin did not prevent nor restore ovariectomy-induced bone loss in adult rats. J. Musculoskelet. Neuronal. Interact. 6, 277 (2006)
65 Bone, H. G., Kiel, D. P., Lindsay, R. S., Lewiecki, E. M., Bolognese, M. A., Leary, E. T., Lowe, W. and McClung, M. R. : Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: A double-blind, placebo-controlled, dose-ranging trial. J. Clin. Endocrinol. Metab. 92, 4671 (2007)   DOI   ScienceOn
66 Sirola, J., Sirola, J., Honkanen, R., Krger, H., Jurvelin, J. S., MenpP. and Saarikoski, S. : Relation of statin use and bone loss: a prospective population-based cohort study in early postmenopausal women. Osteoporos. Int. 13, 537 (2002)   DOI   ScienceOn
67 Serin-Kilicoglu, S. and Erdemli, E. : New addition to the statin's effect. J. Trauma 63, 187 (2007)   DOI   ScienceOn